Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.

[1]  D. Witt,et al.  Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding , 2015, Thrombosis and Haemostasis.

[2]  Michael J Pencina,et al.  Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation , 2017, JAMA.

[3]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[4]  E. Antman,et al.  Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. , 2016, The American journal of medicine.

[5]  L. Køber,et al.  Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. , 2012, European heart journal.

[6]  D. Xavier,et al.  Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. , 2015, American heart journal.

[7]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[8]  A. Haeberli,et al.  Rebound after cessation of oral anticoagulant therapy: the biochemical evidence , 1996, British journal of haematology.

[9]  J. Harenberg,et al.  Plasma hypercoagulability after termination of oral anticoagulants. , 1983, Thrombosis research.

[10]  J. Broderick,et al.  Withdrawal of Antithrombotic Agents and Its Impact on Ischemic Stroke Occurrence , 2011, Stroke.

[11]  Zaid Alirhayim,et al.  Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. , 2014, The American journal of cardiology.

[12]  L. Poller,et al.  EVIDENCE FOR "REBOUND" HYPERCOAGULABILITY AFTER STOPPING ANTICOAGULANTS. , 1964, Lancet.

[13]  D. Singer,et al.  Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation , 2010, Circulation. Cardiovascular quality and outcomes.

[14]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[15]  C. Legnani,et al.  Activation of Blood Coagulation after Abrupt or Stepwise Withdrawal of Oral Anticoagulants - A Prospective Study , 1994, Thrombosis and Haemostasis.

[16]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[17]  E. Antman,et al.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). , 2010, American heart journal.

[18]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[19]  A. Laupacis,et al.  Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis , 2006, BMJ : British Medical Journal.

[20]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .